NCT04743934View on ClinicalTrials.gov

Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 2, 2021

Primary Completion Date

March 1, 2025

Study Completion Date

March 31, 2026

Conditions
Prostate Adenocarcinoma
Interventions
DRUG

Flibanserin 100 MG

Flibanserin 100mg tablets taken by mouth daily at bedtime

DRUG

Placebo

Visually identical placebo tablets taken by mouth daily at bedine

DRUG

Androgen deprivation therapy

Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.

Trial Locations (1)

35233

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Andrew McDonald

OTHER